Health-care costs of losartan and candesartan in the primary treatment of hypertension

Journal of Human Hypertension

Volumn 25, Issue 2, 2011, Pages 130-136

  Henriksson, M ^a   Russell, D ^b   Bodegard, J ^a   Kjeldsen, S ^c   Hasvold, P ^a   Stlhammar, J ^d   Levin, L A ^e  

^a ASTRAZENECA R AND D   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

blood pressure; cardiovascular disease; cost analysis; economic evaluation

Indexed keywords

CANDESARTAN; LOSARTAN; LOSARTAN POTASSIUM;

ARTICLE; CARDIOVASCULAR RISK; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; OUTPATIENT; PRESCRIPTION; RISK REDUCTION;

ACUTE CORONARY SYNDROME; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BRAIN ISCHEMIA; DRUG COSTS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYPERTENSION; LONG-TERM CARE; LOSARTAN; REGISTRIES; SWEDEN; TETRAZOLES;

EID: 78651395786     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.36     Document Type: Article

References (18)

1. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289(18): 2363-2369.
2. Messerli FH, Williams B, Ritz E. Essential hyperten-sion. Lancet 2007; 370(9587): 591-603.
3. DahlofB, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
4. Jonsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlof B. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens 2005; 23(7): 1425-1431.
5. Pfeffer MA, Swedberg K, Granger CB, Held P, McMur-ray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-766.
6. McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R et al. Resource utilization and costs in the candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) pro-gramme. Eur Heart J 2006; 27(12): 1447-1458.
7. Kjeldsen SE, Stalhammar J, Hasv P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hyper-tension\an observational study of 14100 patients. J Hum Hypertens 2009; 24(4): 263-273.
8. Hjelmgren J, Berggren F, Andersson F Health econom-ic guidelines\similarities, differences and some im-plications. Value Health 2001; 4(3): 225-250.
9. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G Methods for the Economic Evaluation of Health Care Programmes, 3rd (edn.) Oxford University Press: Oxford, 2005.
10. Björkenstam C. The Causes of Death Register. The Centre for Epidemiology, The National Board ofHealth and Welfare: Stockholm, 2008.
11. Edberg A, Forsberg L, Jacobsson A, Nykvist K. The National Patient Register. The Centre for Epidemio-logy, The National Board of Health and Welfare: Stockholm, 2008.
12. The Dental and Pharmaceutical Benefits Agency (TLV). Price database (accessed on October 2009); Available at: http://www.tlv.se/in-english/price- database/.
13. Regionva°rdsnämnden. Prices for the South East County Council Region 2008 (accessed on October 2009); Available at: http://www.lio.se/upload/ 16047/20071218Prislista2008totversion2.pdf.
14. Laboratory Medicine Ostergötland, Sweden. Prices of laboratory medicine services (accessed on October 2009); Available at: http://lio.se/ upload/88036/Ny-PL%2008 2009 0615%20(2).pdf.
15. National Board ofHealth and Welfare and SKL. Cost of care 2007 for Nord DRG (accessed on October 2009); Available at: http://www.skl.se/artikeldokument. asp? C = 473&A = 58810&FileID = 247583&NAME = Rapport %5Fkostnadsdata%5F2007.pdf.
16. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrica 2000; 87: 329-343.
17. Glick H, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford University Press: Oxford, 2007.
18. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-1200.